| First Author | Devaux B | Year | 1997 |
| Journal | J Neuroimmunol | Volume | 75 |
| Issue | 1-2 | Pages | 169-73 |
| PubMed ID | 9143251 | Mgi Jnum | J:41336 |
| Mgi Id | MGI:893761 | Doi | 10.1016/s0165-5728(97)00019-2 |
| Citation | Devaux B, et al. (1997) Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. J Neuroimmunol 75(1-2):169-73 |
| abstractText | Myelin oligodendrocyte glycoprotein (MOG) is a transmembrane glycoprotein expressed on the surface of central nervous system (CNS) myelin membranes, which has been shown to induce experimental autoimmune encephalomyelitis (EAE) in rodents. Here we describe the induction of EAE in SJL and (PLJ X SJL)F1 mice with truncated human recombinant MOG (thr-MOG, amino acids 1-120) which has been expressed in insect cells in soluble form. We show that in SJL mice, immunization with thr-MOG produces an immune response to the 1-30 and the 81-110 regions of the MOG molecule. We also demonstrate effective treatment of thr-MOG-induced EAE in SJL mice with intravenous injections of a single peptide, MOG 91-110. These results support the possibility of treating MS using an antigen dependent approach. |
